Schedule 13G ownership disclosure

Apellis Pharmaceuticals Inc

Security class unavailable · CUSIP: 03753U106

Event date: 2022-12-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
8,820,398
Percent of class
7.9800%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000846087-23-000073
Form type
SC 13G/A
Filer
Apellis Pharmaceuticals, Inc.
CIK
CIK 1492422
Filed
Feb 06, 2023
Reporting period
Dec 30, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub